NICHD Cooperative Multicenter Neonatal Research Network - Utah Center

NICHD 合作多中心新生儿研究网络 - 犹他中心

• 批准号: 8456083
• 负责人: ROGER G FAIX
• 金额: $ 0.67万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2016-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8456083
• 关键词: Admission activity; Age; Age-Months; Applied Research; Caring; Child; Childhood; Clinical; Clinical Research; Core Facility; County; Emergency Care; Enrollment; Genetic; Goals; Health Sciences; Heart Diseases; Infant; Information Systems; Institutes; Institution; Instruction; Location; Low Birth Weight Infant; Mission; Multicenter Neonatal Research Network; National Children' s Study; National Institute of Child Health and Human Development; Neonatal; Neonatology; Neurodevelopmental Impairment; Newborn Infant; Outcome; Participant; Pathologic; Patients; Phenotype; Population; Population Database; Positioning Attribute; Productivity; Protocols documentation; Research; Resources; Rest; Site; Societies; Sodium Chloride; Specific qualifier value; Testing; Thyroxine; Universities; Utah; Woman; base; cost effective; data sharing; demographics; fetal medicine; follow-up; high risk; improved; pediatric department; pediatric pharmacology; programs; public health relevance

DESCRIPTION (provided by applicant): This is the application of the Division of Neonatology at the University of Utah to continue in the Cooperative Multicenter Neonatal Research Network (NRN). The NRN objective is to conduct rigorous clinical research in the care of high-risk (particularly low birth weight) newborn infants, by providing sufficient diverse patient availability to answer important clinical questions in a timely, powerful and generalizable manner. Our NICUs remain well positioned to further these objectives. Specific strengths that the Division offers include: 1. Productive contributions to the Network during the 2006 cycle. 2. More than 2,000 admissions to our NICUs and over 9,500 on-site deliveries annually, with demographic mix different from the rest of the NRN. 3. A collaborative and productive relationship with our Division of Maternal Fetal Medicine, an exemplary participant in the NICHD Maternal Fetal Medicine Network (MFMU) that shares data and resources with us. Our continued participation in the NRN will benefit both networks. 4. Numerous other available resources remain: a) Utah Population Database, a unique resource to investigate genetic bases of newborn pathologic phenotypes; b) University of Utah CCTA and associated core facilities; d) Pediatric Pharmacology Program; e) interaction with multiple other research networks now under the rubric of the new University Institute for Woman and Child, including (but not limited to) the Pediatric Heart Disease Clinical Research Network, Pediatric Emergency Care Applied Research Network, the National Children's Study (Salt Lake County is a Vanguard Location and the University Department of Pediatrics is a Vanguard Center), the MFMU, and the NRN. To show how these resources can be used to answer important questions in low birth weight infants, we propose a study testing the hypothesis that thyroxine treatment of VLBW infants >7 days old with transient hypothyroxinemia will result in improved survival without neurodevelopmental impairment at 18-22 months. In summary, this application presents our continued commitment to further the clinical research mission of the NICHD NRN.

描述（由申请人提供）：这是犹他大学新生儿科继续加入合作多中心新生儿研究网络（NRN）的申请。 NRN 的目标是通过提供足够多样化的患者来及时、有力和普遍地回答重要的临床问题，从而在高风险（特别是低出生体重）新生儿的护理方面进行严格的临床研究。我们的新生儿重症监护室仍然处于有利地位，可以进一步实现这些目标。该部门的具体优势包括： 1. 在 2006 年周期内对网络做出富有成效的贡献。 2. 每年有超过 2,000 例入院新生儿重症监护室，并有超过 9,500 例现场分娩，其人口结构与 NRN 的其他地方不同。 3. 与我们的母胎医学部门建立了富有成效的合作关系，该部门是 NICHD 母胎医学网络 (MFMU) 的模范参与者，与我们共享数据和资源。我们继续参与 NRN 将使两个网络受益。 4. 还有许多其他可用资源： a) 犹他州人口数据库，这是研究新生儿病理表型遗传基础的独特资源； b) 犹他大学 CCTA 及相关核心设施； d) 儿科药理学项目； e) 与目前在新的大学妇女儿童研究所的标题下的多个其他研究网络进行互动，包括（但不限于）小儿心脏病临床研究网络、儿科紧急护理应用研究网络、国家儿童研究（盐湖县是先锋地点，大学儿科系是先锋中心）、MFMU 和 NRN。为了展示如何利用这些资源来回答低出生体重婴儿的重要问题，我们提出了一项研究，测试以下假设：对 7 天以上、患有短暂性低甲状腺素血症的 VLBW 婴儿进行甲状腺素治疗，可提高 18-22 个月时的生存率，且不会出现神经发育障碍。总之，该申请体现了我们对进一步完成 NICHD NRN 临床研究使命的持续承诺。